Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen and Quest to Develop Arterial Disease Dx

NEW YORK (GenomeWeb News) — Ciphergen and Quest Diagnostics plan to jointly develop a blood-based test for the detection of peripheral artery disease.
The deal is the second of a three-part alliance the firms formed last year in which Quest will use Ciphergen’s SELDI-based ProteinChip technology to create the test. The first incarnation resulted in a test that triages ovarian cancer.
As part of that deal, Quest bought a 17-percent stake in Ciphergen and agreed to a five-year warrant to by another 2.2 million shares at $3.50 a share, for an aggregate of $15 million.
Under that alliance, Quest also agreed to loan Ciphergen as much as $10 million for research expenses, which would be forgiven based on milestone achievements.  
Today, Ciphergen President and CEO Gail Page said the ovarian tumor test is “making excellent progress.”
Ciphergen said it is developing the PAD blood test with Stanford University. The company said that 75 percent of the people who suffer from PAD, which is caused by arterial plaque, do not experience symptoms, which could make an early warning test valuable.  
Financial terms of this agreement were not released.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.